Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 59Neoplasms 6Neoplasm Metastasis 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Ovarian Neoplasms 3Neoplasms by Site 3Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neuroblastoma 2Multiple Endocrine Neoplasia Type 1 2Lymphoma 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteitis Deformans 1Neoplasms, Germ Cell and Embryonal 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EGFR-mutant Non-small Cell Lung Cancer × ribociclib × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡